Radiolabeled HER3 Agents for Solid Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are inadequate in targeting HER3-positive cancers, as existing treatments often result in downregulation of the HER3 target, limiting the effectiveness of repeat dosing and tumor targeting.
Innovation Solution
Development of radiolabeled HER3 targeting agents, such as monoclonal antibodies or small molecules, conjugated with radioisotopes like 225Ac, 177Lu, or 131I, which can be administered alone or in combination with other therapeutic agents to effectively diagnose and treat HER3-positive cancers without causing significant downregulation of the HER3 target.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies targeting HER3 are administered, then initial tumor targeting is achieved, but the HER3 target becomes downregulated, limiting the effectiveness of repeat dosing
Solution Approach 1:
The patent employs dynamic dosing strategies where the timing and frequency of radiolabeled antibody administration are optimized based on the pharmacokinetics of the radiotracer and the biology of HER3 expression. This allows maintenance of therapeutic efficacy while minimizing target downregulation through adaptive treatment schedules
Solution Approach 2:
The invention utilizes radiolabeled antibodies with different half-lives and dosing regimens to alter the temporal parameters of target engagement. By changing the radioactive isotope used (e.g., 89Zr vs 111In) and adjusting administered activity levels, the patent optimizes the balance between achieving sufficient radiation dose to tumors and maintaining HER3 target availability for repeat dosing
2Productivity
If high doses of HER3-targeting agents are administered to improve tumor killing, then therapeutic efficacy increases, but normal tissues experience increased toxicity
Solution Approach 1:
The patent replaces conventional mechanical chemotherapy delivery with radiological therapy using radiolabeled antibodies. This substitution allows for more precise energy deposition in tumor tissues through beta and alpha particle emission, achieving higher local cytotoxicity while sparing normal tissues due to the limited range of radioactive particles in tissue
Solution Approach 2:
The radiolabeled antibody serves as an intermediary that delivers radioactive isotopes specifically to HER3-expressing tumor cells. The antibody component provides selective binding to the target, while the radioactive isotope (e.g., 89Zr, 177Lu, 225Ac) delivers cytotoxic radiation, separating the targeting function from the killing function to improve therapeutic index
3Reliability
If radiolabeled HER3 targeting agents are used to improve tumor targeting, then diagnostic and therapeutic efficacy increases, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent employs radiolabeled antibodies that serve dual diagnostic and therapeutic functions (theranostics). The same radiolabeled HER3-targeting agent can be used for both imaging (diagnosis) and radiation therapy (treatment), eliminating the need for separate diagnostic and therapeutic agents and simplifying the overall protocol
Solution Approach 2:
The treatment protocol utilizes periodic administration of radiolabeled antibodies at optimized intervals that account for the physical half-life of the radioactive isotope and the biological half-life of antibody clearance. This periodic dosing schedule simplifies treatment planning while maintaining effective tumor targeting over time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The radiolabeled HER3 targeting agents provide improved tumor targeting and killing of HER3-expressing cancer cells, maintaining therapeutic efficacy without detrimental downregulation, and can be used in combination with immune checkpoint therapies, DNA damage response inhibitors, or CD47 blockades for enhanced treatment outcomes.
Implementation Method 1
labeled with a radioisotope
Implementation Method 2
radiolabeled HER3 targeting agent... killing of HER3-expressing cancer cells
Data Source
AI summary
Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities. The effective amount of the radiolabeled HER3-targeting agent may be a maximum tolerate dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose.